Cell & Gene Therapy Manufacturing Services Market Size, 2032

Cell & Gene Therapy Manufacturing Services Market - By Type [Cell (Allogenic, Autogenic), Gene], Mode (Contract, In-house), Indication (Oncology, Cardiovascular), End-user (Biopharmaceutical, Academic & Research Institute), Global Forecast 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of cancer and other diseases

3.2.1.2&nbsp;&nbsp;&nbsp; Increasing government grants and support for development of cell and gene therapies

3.2.1.3&nbsp;&nbsp;&nbsp; Increasing pharmaceutical R&amp;D spending

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High risk of mutagenesis

3.2.2.2&nbsp;&nbsp;&nbsp; Lack of standardized production systems for cell and gene therapy products

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; U.S.

3.4.2&nbsp;&nbsp;&nbsp; Canada

3.4.3&nbsp;&nbsp;&nbsp; Europe

3.5&nbsp;&nbsp;&nbsp; Technology landscape

3.6&nbsp;&nbsp;&nbsp; Pipeline analysis

3.7&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.8&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2023

4.1&nbsp;&nbsp;&nbsp; Introduction

4.1.1&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific Inc.

4.1.2&nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH

4.1.3&nbsp;&nbsp;&nbsp; Merck KGaA

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.3&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.4&nbsp;&nbsp;&nbsp; Company matrix analysis

4.5&nbsp;&nbsp;&nbsp; Vendor matrix analysis

4.6&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.7&nbsp;&nbsp;&nbsp; Strategy dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Type, 2018 &ndash; 2032 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Cell therapy

5.2.1&nbsp;&nbsp;&nbsp; Allogenic

5.2.1.1&nbsp;&nbsp;&nbsp; Mesenchymal stem cells

5.2.1.2&nbsp;&nbsp;&nbsp; T-cells

5.2.1.3&nbsp;&nbsp;&nbsp; Natural killer cells

5.2.1.4&nbsp;&nbsp;&nbsp; Hematopoietic stem cells

5.2.1.5&nbsp;&nbsp;&nbsp; Other allogeneic cells

5.2.2&nbsp;&nbsp;&nbsp; Autologous

5.2.2.1&nbsp;&nbsp;&nbsp; Mesenchymal stem cells

5.2.2.2&nbsp;&nbsp;&nbsp; T-cells

5.2.2.3&nbsp;&nbsp;&nbsp; Natural killer cells

5.2.2.4&nbsp;&nbsp;&nbsp; Hematopoietic stem cells

5.2.2.5&nbsp;&nbsp;&nbsp; Other allogeneic cells

5.3&nbsp;&nbsp;&nbsp; Gene therapy

5.3.1&nbsp;&nbsp;&nbsp; Viral vectors

5.3.2&nbsp;&nbsp;&nbsp; Non-viral vectors

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Mode, 2018 &ndash; 2032 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Contract manufacturing

6.3&nbsp;&nbsp;&nbsp; In-house manufacturing

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Indication, 2018 &ndash; 2032 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Oncology diseases

7.3&nbsp;&nbsp;&nbsp; Cardiovascular diseases

7.4&nbsp;&nbsp;&nbsp; Orthopedic diseases

7.5&nbsp;&nbsp;&nbsp; Infectious diseases

7.6&nbsp;&nbsp;&nbsp; Ophthalmology diseases

7.7&nbsp;&nbsp;&nbsp; Other indications

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End user, 2018 &ndash; 2032 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Biopharmaceutical companies

8.3&nbsp;&nbsp;&nbsp; Academic research institutes

8.4&nbsp;&nbsp;&nbsp; Hospitals

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2018 &ndash; 2032 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East and Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH

10.2&nbsp;&nbsp;&nbsp; Bluebird Bio, Inc.

10.3&nbsp;&nbsp;&nbsp; Catalent, Inc.

10.4&nbsp;&nbsp;&nbsp; Charles River Laboratories International, Inc.

10.5&nbsp;&nbsp;&nbsp; Merck KGaA

10.6&nbsp;&nbsp;&nbsp; Miltenyi Bioindustry (Miltenyi Biotec)

10.7&nbsp;&nbsp;&nbsp; Samsung Biologics

10.8&nbsp;&nbsp;&nbsp; Takara Bio Inc.

10.9&nbsp;&nbsp;&nbsp; Thermo Fisher Scientific Inc

10.10&nbsp;&nbsp;&nbsp; WuXi AppTec Co., Ltd. 
&nbsp;

Cell Gene Therapy Manufacturing Services Market

Get a free sample of this report